Oxford Immunotec (OXFD) 8.81 $OXFD
Oxford Immunotec Enters into Definitive Agreement to Acquire Imugen
Globe Newswire - Thu Jun 23, 3:05PM CDT
OXFORD, United Kingdom and MARLBOROUGH, Mass., June 23, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced it has entered into a definitive agreement to acquire substantially all of the assets of Imugen, Inc., a Massachusetts-based clinical laboratory focused on developing and performing specialized testing for tick-borne diseases, for $22.2 million in an all cash transaction expected to close on July 1, 2016.
OXFD: 8.81 (unch)
Oxford Immunotec to Present at the Jefferies 2016 Healthcare Conference
Globe Newswire - Fri May 20, 10:45AM CDT
OXFORD, United Kingdom and MARLBOROUGH, Mass., May 20, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, and Rick Altieri, Chief Financial Officer, will present at the Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016, at 2:00 p.m. ET at the Grand Hyatt in New York, NY.
OXFD: 8.81 (unch)
Oxford Immunotec reports 1Q loss
Automated Insights - Tue May 03, 7:54AM CDT
ABINGDON, Britain (AP) _ Oxford Immunotec Global PLC (OXFD) on Tuesday reported a loss of $7 million in its first quarter.
OXFD: 8.81 (unch)
Oxford Immunotec Reports First Quarter 2016 Financial Results
Globe Newswire - Tue May 03, 6:00AM CDT
- First quarter revenue of $17.1 million, increased 24% compared to prior year period
OXFD: 8.81 (unch)
Oxford Immunotec Schedules First Quarter 2016 Earnings Release and Conference Call for May 3, 2016
Globe Newswire - Wed Apr 20, 10:08AM CDT
OXFORD, United Kingdom and MARLBOROUGH, Mass., April 20, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced that it plans to release first quarter 2016 financial results prior to market open on Tuesday, May 3, 2016. Dr. Peter Wrighton-Smith, Chief Executive Officer, and Rick Altieri, Chief Financial Officer, will host a conference call to review the Company's results at 8:00 a.m. Eastern Time the same day. The call will be concurrently webcast.
OXFD: 8.81 (unch)
Oxford Immunotec Takes Active Role in Raising Awareness of TB Testing and Prevention during World TB Day
Globe Newswire - Thu Mar 24, 8:00AM CDT
OXFORD, United Kingdom and MARLBOROUGH, Mass., March 24, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced the company's commitment to building awareness of TB testing and prevention during World TB Day on March 24, 2016 through its support of educational programs around the world.
OXFD: 8.81 (unch)
Oxford Immunotec Global appoints Patrick J. Balthrop, Sr. to board
M2 - Tue Feb 02, 3:04AM CST
Diagnostics company Oxford Immunotec Global (NasdaqGM:OXFD) revealed on Monday the election of Patrick J. Balthrop, Sr. to its board of directors.
OXFD: 8.81 (unch), LMNX: 21.72 (+0.06)
Patrick J. Balthrop, Sr., Former CEO of Luminex, Joins Oxford Immunotec Board of Directors
Globe Newswire - Mon Feb 01, 4:00PM CST
OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 01, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced the appointment of Patrick J. Balthrop, Sr. to its Board of Directors.
OXFD: 8.81 (unch), LMNX: 21.72 (+0.06)
Oxford Immunotec to Present at the LEERINK Partners 5th Annual Global Healthcare Conference
Thomson Reuters ONE - Tue Jan 26, 11:06AM CST
OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 26, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, will present at the LEERINK Partners 5th Annual Global Healthcare Conference on Wednesday, February 10, 2016, at 1:25 p.m. EST at the Waldorf Astoria in New York, NY.
OXFD: 8.81 (unch)
Oxford Immunotec awarded CE Mark for the T-SPOT.PRT Test for the transplantation market
M2 - Wed Dec 23, 5:03AM CST
Diagnostics company Oxford Immunotec Global PLC (NasdaqGM:OXFD) reported on Tuesday that it has received CE marking for the T-SPOT.PRT test to help transplant patients and physicians manage immune regulated conditions.
OXFD: 8.81 (unch)
Oxford Immunotec Announces CE Mark for the T-SPOT.PRT Test
Thomson Reuters ONE - Tue Dec 22, 3:45PM CST
OXFORD, United Kingdom and MARLBOROUGH, Mass., Dec. 22, 2015 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced that it gained CE marking for the T-SPOT(R).PRT test. The panel of reactive T cells (PRT) test assesses a solid organ transplant candidate's T cell response to foreign tissue, referred to as alloreactivity.
OXFD: 8.81 (unch)
Oxford Immunotec to Present at the 34th Annual J.P. Morgan Healthcare Conference
Thomson Reuters ONE - Fri Dec 18, 2:07PM CST
OXFORD, United Kingdom and MARLBOROUGH, Mass., Dec. 18, 2015 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, and Richard Altieri, Chief Financial Officer, will present at the 34th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2016, at 2:30 p.m. PST (5:30 p.m. EST) at the Westin St. Francis on Union Square in San Francisco, CA.
JPM: 62.27 (+0.44), OXFD: 8.81 (unch)
Oxford Immunotec Enters into Definitive Agreement to Acquire Imugen
Globe Newswire - Thu Jun 23, 3:05PM CDT
OXFORD, United Kingdom and MARLBOROUGH, Mass., June 23, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced it has entered into a definitive agreement to acquire substantially all of the assets of Imugen, Inc., a Massachusetts-based clinical laboratory focused on developing and performing specialized testing for tick-borne diseases, for $22.2 million in an all cash transaction expected to close on July 1, 2016.
OXFD: 8.81 (unch)
Oxford Immunotec to Present at the Jefferies 2016 Healthcare Conference
Globe Newswire - Fri May 20, 10:45AM CDT
OXFORD, United Kingdom and MARLBOROUGH, Mass., May 20, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, and Rick Altieri, Chief Financial Officer, will present at the Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016, at 2:00 p.m. ET at the Grand Hyatt in New York, NY.
OXFD: 8.81 (unch)
Oxford Immunotec reports 1Q loss
Automated Insights - Tue May 03, 7:54AM CDT
ABINGDON, Britain (AP) _ Oxford Immunotec Global PLC (OXFD) on Tuesday reported a loss of $7 million in its first quarter.
OXFD: 8.81 (unch)
Oxford Immunotec Reports First Quarter 2016 Financial Results
Globe Newswire - Tue May 03, 6:00AM CDT
- First quarter revenue of $17.1 million, increased 24% compared to prior year period
OXFD: 8.81 (unch)
Oxford Immunotec Schedules First Quarter 2016 Earnings Release and Conference Call for May 3, 2016
Globe Newswire - Wed Apr 20, 10:08AM CDT
OXFORD, United Kingdom and MARLBOROUGH, Mass., April 20, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced that it plans to release first quarter 2016 financial results prior to market open on Tuesday, May 3, 2016. Dr. Peter Wrighton-Smith, Chief Executive Officer, and Rick Altieri, Chief Financial Officer, will host a conference call to review the Company's results at 8:00 a.m. Eastern Time the same day. The call will be concurrently webcast.
OXFD: 8.81 (unch)
Oxford Immunotec Takes Active Role in Raising Awareness of TB Testing and Prevention during World TB Day
Globe Newswire - Thu Mar 24, 8:00AM CDT
OXFORD, United Kingdom and MARLBOROUGH, Mass., March 24, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced the company's commitment to building awareness of TB testing and prevention during World TB Day on March 24, 2016 through its support of educational programs around the world.
OXFD: 8.81 (unch)
Oxford Immunotec Global appoints Patrick J. Balthrop, Sr. to board
M2 - Tue Feb 02, 3:04AM CST
Diagnostics company Oxford Immunotec Global (NasdaqGM:OXFD) revealed on Monday the election of Patrick J. Balthrop, Sr. to its board of directors.
OXFD: 8.81 (unch), LMNX: 21.72 (+0.06)
Patrick J. Balthrop, Sr., Former CEO of Luminex, Joins Oxford Immunotec Board of Directors
Globe Newswire - Mon Feb 01, 4:00PM CST
OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 01, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced the appointment of Patrick J. Balthrop, Sr. to its Board of Directors.
OXFD: 8.81 (unch), LMNX: 21.72 (+0.06)
Oxford Immunotec to Present at the LEERINK Partners 5th Annual Global Healthcare Conference
Thomson Reuters ONE - Tue Jan 26, 11:06AM CST
OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 26, 2016 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, will present at the LEERINK Partners 5th Annual Global Healthcare Conference on Wednesday, February 10, 2016, at 1:25 p.m. EST at the Waldorf Astoria in New York, NY.
OXFD: 8.81 (unch)
Oxford Immunotec awarded CE Mark for the T-SPOT.PRT Test for the transplantation market
M2 - Wed Dec 23, 5:03AM CST
Diagnostics company Oxford Immunotec Global PLC (NasdaqGM:OXFD) reported on Tuesday that it has received CE marking for the T-SPOT.PRT test to help transplant patients and physicians manage immune regulated conditions.
OXFD: 8.81 (unch)
Oxford Immunotec Announces CE Mark for the T-SPOT.PRT Test
Thomson Reuters ONE - Tue Dec 22, 3:45PM CST
OXFORD, United Kingdom and MARLBOROUGH, Mass., Dec. 22, 2015 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced that it gained CE marking for the T-SPOT(R).PRT test. The panel of reactive T cells (PRT) test assesses a solid organ transplant candidate's T cell response to foreign tissue, referred to as alloreactivity.
OXFD: 8.81 (unch)
Oxford Immunotec to Present at the 34th Annual J.P. Morgan Healthcare Conference
Thomson Reuters ONE - Fri Dec 18, 2:07PM CST
OXFORD, United Kingdom and MARLBOROUGH, Mass., Dec. 18, 2015 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions, today announced that Dr. Peter Wrighton-Smith, Chief Executive Officer, and Richard Altieri, Chief Financial Officer, will present at the 34th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2016, at 2:30 p.m. PST (5:30 p.m. EST) at the Westin St. Francis on Union Square in San Francisco, CA.
JPM: 62.27 (+0.44), OXFD: 8.81 (unch)
